title: Evaluating the effects of 14-day oral vedaprofen and tolfenamic acid treatment on renal function, hematological and biochemical profiles in healthy cats.
abstract: The objective of this study was to evaluate the effects of the nonsteroidal anti-inflammatory drugs vedaprofen and tolfenamic acid on renal function after oral administration for 2 weeks in healthy cats. Experiments were performed using nineteen domestic short-haired cats randomly divided into one control (n=6) and two treatment groups. All cats in the first (n=6) and second treatment groups (n=7) received vedaprofen (0.5 mg/kg/day) and tolfenamic acid (4 mg/kg/day), respectively. During the experiment, renal function was evaluated using percent renal uptakes of (99m)Technetium-diethylenetriamine-pentaacetic acid ((99m)Tc-DTPA) collected from renal scintigraphy and blood samples used to determine complete blood count and biochemical profiles. Renal scintigraphy and blood collections were performed at days 0, 5, 11, 15, and 45. The percent of renal uptake after the administration of vedaprofen and tolfenamic acid were not significantly different compared to pretreatment (day 0) and control group levels. In addition, significant changes were not observed in hematological and biochemical profiles within or between groups, with the exception of slightly lower numbers in red blood cell counts compared to the normal value on day 45 in the tolfenamic acid-treated group. Taken together, we conclude 14-day administration of vedaprofen and tolfenamic acid might not cause any adverse effects on renal function, hematological and serum biochemical variables.
authors.affiliation: Department of Pharmacology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
authors.forename: V
authors.initials: V
authors.lastname: Khwanjai
authors.forename: S
authors.initials: S
authors.lastname: Chuthatep
authors.forename: S
authors.initials: S
authors.lastname: Durongphongtorn
authors.forename: S
authors.initials: S
authors.lastname: Yibchok-Anun
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D002371:Cat Diseases / Q000097:blood / Q000139:chemically induced*; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004906:Erythrocyte Count / Q000662:veterinary; D007674:Kidney Diseases / Q000139:chemically induced / Q000662:veterinary*; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D011422:Propionates / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D016284:Technetium Tc 99m Pentetate / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009281:Naphthalenes; D011422:Propionates; D062367:ortho-Aminobenzoates; C009500:tolfenamic acid; C121784:2-(4-cyclohexyl-1-naphthalenyl)propanoic acid; D016284:Technetium Tc 99m Pentetate